Pricing Sign in

BCYC

BicycleTx Limiteddistress 4/10 · elevated risk

$4.14-2%today-53% from 52w high

bicycletherapeutics.com288 employeesFounded 2009Cambridge, United KingdomBiotechnology

Oncology 2

Lead: metastatic urothelial cancer · target PD-1

Revenue

pre-revenue

Liquidity

$559M

Runway

2.4 yrs

Shares 1y

+68%

Price & events

-42.7% over 6M

CatalystRating changeDilutionFinancingdashed = today

-1.7%

1D

-1.0%

1W

+3.5%

1M

-14.6%

3M

-40.4%

6M

-52.5%

1Y

-82.6%

2Y

-88.3%

5Y

-78.4%

All

Overview

Market Cap: $124.38M
Volume: 8.34K
52 Week Range: $3.96 – $8.87
Total Shares: 30.04M
Short %: 7.42%
% Held by Insiders: 4.49%
% Held by Institutions: 73.77%
RVOL: 0.02x
Beta: 1.55

Pipeline stages · 4 programs

BT5528, NivolumabPD-1

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-07-31

BT7480, NivolumabPD-1

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-08

Zelenectide pevedotin, BT7480, Nuzefatide pevedotin

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2028-03

nuzefatide pevedotin (BT5528)

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2029-03

Pipeline · 7 trials · 7 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2026-07-31 Estimated 50% readout ~2026-09-14 final ~2027-07-31	Phase 1/2	BT5528, Nivolumab	Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer	—	active not recruiting
2026-08 Estimated 50% readout ~2026-09-15 final ~2027-02-28	Phase 1/2	BT7480, Nivolumab	Advanced Solid Tumor	—	active not recruiting
2028-03 Estimated 50% readout ~2028-04-15	Phase 2	Zelenectide pevedotin, Pembrolizumab, Gemcitabinefast track	Metastatic Urothelial Cancer	—	active not recruiting
2028-06-30 Estimated 50% readout ~2028-08-14	Phase 2	Zelenectide pevedotin (BT8009)fast track	Breast Cancer	—	active not recruiting
2028-08-31 Estimated 50% readout ~2028-10-15	Phase 2	Zelenectide pevedotinfast track	Non-Small Cell Lung Cancer	—	active not recruiting

Show all 7 trials · 2 more ▾

Readout	Phase	Drug	Indication	Enroll	Status
2029-03 Estimated 50% readout ~2029-04-15	Phase 2	nuzefatide pevedotin (BT5528)	Pancreatic Ductal Adenocarcinoma (PDAC)	—	recruiting
2030-05-30 Estimated 50% readout ~2030-07-14	Phase 2	Zelenectide pevedotin, BT7480, Nuzefatide pevedotinfast track	Advanced Solid Tumors	—	not yet recruiting

Catalyst news & presentations · 18

second half of 2026Guided 55%conferencedata presentationsecondaryPhase 1/2zelenectide pevedotin · Report initial Phase 1/2 Duravelo-3 trial dataSEC 8-K
2026Guided 40%trial initiationsecondaryFirst company-sponsored radiopharmaceutical clinical trials planned.SEC 8-K
2026-08-07earningsEarningsEarnings releaseyahoo
first half of 2026conferencedata presentationsecondaryPhase 1BT7480 · Report Phase 1 BT7480 combination data with nivolumabSEC 8-K
first half of 2026conferencedata presentationsecondaryPhase 1BT5528 · Report Phase 1 BT5528 combination data with nivolumabSEC 8-K
first half of 2026conferencedata presentationsecondaryEphA2 BRC · Report additional EphA2 human imaging dataSEC 8-K
first half of 2026conferencedata presentationsecondaryPhase 1zelenectide pevedotin · Report longer-term follow-up Phase 1 Duravelo-1 monotherapy data in late-line mUCSEC 8-K
first quarter of 2026readoutPhase 2/3zelenectide pevedotin · Dose selection update for Duravelo-2 trial and potential approval pathwaySEC 8-K
2025trial initiationsecondaryPhase 1/2zelenectide pevedotin · Initiate Phase 1/2 trials in NECTIN4 gene-amplified tumorsSEC 8-K
second half of 2025readoutPhase 2/3zelenectide pevedotin · Dose selection and topline data from Phase 2/3 Duravelo-2 trialSEC 8-K
2H 2025conferencedata presentationsecondaryEphA2 BRC · Initial human imaging data for second BRC molecule targeting EphA2 expected.SEC 8-K
4Q 2025readoutPhase 1BT7480 · Report Phase 1 combination data for BT7480 plus nivolumabSEC 8-K
4Q 2025readoutPhase 1BT5528 · Report Phase 1 combination data for BT5528 plus nivolumabSEC 8-K
mid-2025conferencedata presentationsecondaryMT1-MMP BRC · Report additional MT1-MMP human imaging dataSEC 8-K
first half of 2025trial initiationsecondaryPhase 1zelenectide pevedotin · Initiate Phase 1 Duravelo-3 trial in NECTIN4 gene-amplified breast cancerSEC 8-K
September 14, 2024conferencedata presentationsecondaryPhase 1/2BT7480 · Initial Phase 1/2 dose escalation data for BT7480 at ESMO.SEC 8-K
September 14, 2024conferencedata presentationsecondaryPhase 1/2BT5528 · Updated Phase 1/2 results for BT5528 at ESMO.SEC 8-K
September 14, 2024conferencedata presentationsecondaryPhase 1/2zelenectide pevedotin · Updated Phase 1/2 results presented at ESMO Congress 2024.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 30,043,486 · 1 offerings/1y · 0 PIPEs

2025-08-14424B3offering
2025-08-14EFFECTshelf_effective
2025-08-08S-3shelf_registration
2024-12-17SC 13D/Astrategic_stake
2024-11-14SC 13G/Astrategic_stake
2024-11-14SC 13G/Astrategic_stake
2024-11-13SC 13G/Astrategic_stake

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Wall St ratings

buy · target $13 (+205% upside) · 8 analysts

2026-04-08Morgan StanleyEqual-Weight
2026-03-18OppenheimerOutperform
2026-03-18CitizensMarket Outperform
2026-03-18RBC CapitalSector Perform
2026-03-18NeedhamBuy
2025-11-24Truist SecuritiesHold

Competitors — PD-1

REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
BEIGFBeOne Medicines Ltd.$31.7B · D1
NCNANuCana plc$28.3B · D2
EXELEXELIXIS, INC.$13.8B · D0
IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
CGEMCullinan Therapeutics, Inc.$1.1B · D1
REPLReplimune Group, Inc.$906M · D2
ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
BCABBioAtla, Inc.$107M · D8
IOBTQIO Biotech, Inc.$71,949 · D5

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.